FINITE CHB - First Investigation in Stopping Tenofovir Disoproxil Fumarate (TDF) Treatment After Long Term Virologic Suppression in HBeAg-negative Chronic Hepatitis B.

Trial Profile

FINITE CHB - First Investigation in Stopping Tenofovir Disoproxil Fumarate (TDF) Treatment After Long Term Virologic Suppression in HBeAg-negative Chronic Hepatitis B.

Completed
Phase of Trial: Phase IV

Latest Information Update: 31 Aug 2017

At a glance

  • Drugs Tenofovir disoproxil fumarate (Primary)
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms FINITE CHB
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 20 Jul 2017 Primary endpoint (Proportion of participants with HBsAg loss at Week 144 in both study arms) has been met,as per the results published in the Journal of Hepatology.
    • 20 Jul 2017 Results published in the Journal of Hepatology
    • 29 Aug 2016 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top